Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Regulation FD Disclosure
Item7.01.Regulation FD Disclosure.
On June 5, 2017, Titan Pharmaceuticals, Inc. posted on its
website an updated corporate presentation, a copy of which is
attached hereto as Exhibit 99.1 and incorporated herein by
reference.
The foregoing information, including the presentation attached
hereto as an exhibit, is being furnished to Item 7.01 of this
Current Report and shall not be deemed filed for the purposes of
Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
This information shall not be incorporated by reference into any
registration statement to the Securities Act of 1933, as amended.
Item9.01. Financial Statement and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Corporate Presentation |
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
